Neon Therapeutics
2013
FOUNDED
PUBLIC
STATUS
101-200
EMPLOYEES
NTGN
STOCK SYMBOL
$5.08
SHARE PRICE
(As of Tuesday Closing)
Description
Neon Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01.
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 40 Erie Street
- Suite 110
- Cambridge, MA 02139
- United States
+1 (617) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Neon Therapeutics’s full profile, request a free trial.
Neon Therapeutics Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $4.20 - $16.23 | $144M | $5.09 | -$9.26 | 153K | 28.3M |
Neon Therapeutics Financials Summary
|
In Thousands,
USD |
TTM
31-Mar-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 79,709 | 237,586 | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (81,996) | (77,268) | (47,185) | (27,022) |
| Net Income | (81,437) | (76,934) | (47,536) | (27,433) |
| Total Assets | 101,040 | 114,088 | 90,493 | 95,261 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Neon Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Neon Therapeutics‘s full profile, request access.
Request full access to PitchBookNeon Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Neon Therapeutics‘s full profile, request access.
Request full access to PitchBookNeon Therapeutics Competitors (54)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| UNUM Therapeutics | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 000000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000000 | 00000 |
| 000 0000000000000 | Private Equity-Backed | Saint Asaph, United Kingdom | 00 | 000.00 | 0000000 0000 | 000.00 |
| 000000000000 | Venture Capital-Backed | Houston, TX | 000.00 | 00000000000 | 000.00 | |
| 0000000 0000000000 | Formerly VC-backed | Richmond, CA | 000 | 000.00 | 00000000 | 000.00 |
Neon Therapeutics Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Neon Therapeutics‘s full profile, request access.
Request full access to PitchBookNeon Therapeutics Executive Team (16)
3 Former Executives
You’re viewing 5 of 16 executives. Get the full list »Neon Therapeutics Board Members (8)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Cary Pfeffer MD | Third Rock Ventures | Chairman | 000 0000 | |
| Eric Lander Ph.D | Neon Therapeutics | Scientific Co-Founder & Board Member | 000 0000 | |
| Hugh O'Dowd | Neon Therapeutics | Chief Executive Officer, President & Board Member | 000 0000 | |
| Julian Adams Ph.D | Clal Biotechnology Industries | Board Member | 000 0000 | |
| Meryl Zausner | Self | Board Member | 000 0000 |